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Abstract
Objective: In a previous cohort study (n=96), we found an association between mitochondrial (mt) DNA haplogroup
JT and increased survival of severe septic patients, after controlling for age and serum lactic acid levels. The aim of
this research was to increase the predictive accuracy and to control for more confounder variables in a larger cohort
(n=196) of severe septic patients, to confirm whether mtDNA haplogroup JT influences short and medium-term
survival in these patients.
Methods: We conducted a prospective, multicenter, observational study in six Spanish Intensive Care Units. We
determined 30-day and 6-month survival and mtDNA haplogroup in this second cohort of 196 patients and in the
global cohort (first and second cohorts combined) with 292 severe septic patients. Multiple logistic regression and
Cox regression analyses were used to test for the association of mtDNA haplogroups JT with survival at 30-days and
6-months, controlling for age, sex, serum interleukin-6 levels and SOFA score.
Results: Logistic and Cox regression analyses showed no differences in 30-day and 6-month survival between
patients with mtDNA haplogroup JT and other haplogroups in the first cohort (n=96). In the second cohort (n=196),
these analyses showed a trend to higher 30-day and 6-month survival in those with haplogroup JT. In the global
cohort (n=292), logistic and Cox regression analyses showed higher 30-day and 6-month survival for haplogroup JT.
There were no significant differences between J and T sub-haplogroups in 30-day and 6-month survival.
Conclusions: The global cohort study (first and second cohorts combined), the largest to date reporting on mtDNA
haplogroups in septic patients, confirmed that haplogroup JT patients showed increased 30-day and 6-month
survival. This finding may be due to single nucleotide polymorphism defining the whole haplogroup JT and not
separately for J or T sub-haplogroups.
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Introduction
Severe sepsis is a common, expensive, and frequently fatal
condition [1,2]. Genetic factors may influence mortality in septic
patients. Sepsis-related polymorphism studies have most
commonly focused on genetic variants for specific genes
whose protein products are elements of biologic pathways
implicated in sepsis. These have included pro- and anti-
inflammatory cytokines, innate immunity and coagulation/
fibrinolysis pathways [3-5].
Although most genetic studies have focused on the immune
system, recovery after sepsis is directly related to physiological
reserve which is critically dependent on mitochondrial function
[6]. Thirteen subunits of the mitochondrial oxidative
phosphorylation system, the major pathway of cellular energy
production, are coded in mitochondrial DNA (mtDNA).
Interestingly, in 137 and 181 septic patients from a Chinese
Han population, mtDNA macrolineage R was found to be a
strong independent predictor of sepsis survival at 30 days [7]
and six-months [8], respectively. In China, this macrolineage is
found in approximately 35% of the population and mainly
includes haplogroups B and F. In Europe, the macrolineage R
includes haplogroups that are different from those of Asia.
Thus, haplogroups HV, U and JT account for around 90% of
the European population. Haplogroup HV contains haplogroup
H. In 148 septic patients from England, haplogroup H was
found to be a strong independent predictor of six-month
outcome in patients with severe sepsis [6]. More recently, in 96
septic patients from Spain, we found that mtDNA haplogroup
JT was associated with higher one-month survival, after
controlling for age and serum lactic acid levels [9].
The aim of this research was to increase the predictive
accuracy and to control for more confounder variables in a
larger cohort (n=196) of severe septic patients, to confirm
whether mtDNA haplogroup JT influences short and medium-
term survival in these patients.
Methods
Design and subjects
A prospective, multicentre observational study was carried
out in six Spanish intensive care units (ICUs). The Institutional
Review Boards of the six hospitals approved this study:
Hospital Universitario de Canarias (La Laguna. Santa Cruz de
Tenerife, Spain), Hospital Universitario Nuestra Señora de
Candelaria (Santa Cruz de Tenerife, Spain), Hospital
Universitario Dr. Negrín (Las Palmas de Gran Canaria, Spain),
Hospital Clínico Universitario de Valencia (Valencia. Spain),
Hospital San Jorge (Huesca, Spain) and Hospital Insular (Las
Palmas de Gran Canaria, Spain). Written informed consent
from the patients or from their family members was obtained.
We included patients with the diagnosis of severe sepsis
according to the criteria of the International Sepsis Definitions
Conference [10]. Exclusion criteria were: age < 18 years,
pregnancy, lactation, infection by human immunodeficiency
virus (HIV), white blood cell count < 1,000/mm3, solid or
haematological tumour, or immunosuppressive, steroid or
radiation therapy.
The following variables were recorded at baseline for each
patient: gender, age, diabetes mellitus, chronic obstructive
pulmonary disease (COPD), ischemic heart disease, ischemic
stroke, site of infection, microorganism responsible,
bloodstream infection, empiric antimicrobial therapy (this was
considered adequate if the microorganism responsible of
sepsis was susceptible at least to one antimicrobial agent
used), mean blood pressure, septic shock, need and dose of
norepinephrine, need and dose of dobutamine, pressure of
arterial oxygen/fraction inspired (PaO2/FIO2), creatinine,
bilirubin, leukocytes, lactic acid, platelets, international
normalized ratio (INR), activated partial thromboplastin time
(aPTT), interleukin-6, Acute Physiology and Chronic Health
Evaluation (APACHE)-II score [11] and sepsis-related organ
failure assessment (SOFA) score [12]. We used survival at 30
days and 6 months as endpoints.
Haplogroup determination
Blood samples were collected from patients at the time of
diagnosis of severe sepsis and frozen at -80°C. DNA was
extracted following standard protocols and mtDNA haplogroup
was determined by real time-polymerase chain reaction (RT-
PCR). Three single nucleotide polymorphisms (SNPs) defining
very frequent haplogroups JT (m.4216C), H (m.7028C) and U
(m.12308G) were genotyped in all the samples. Fourteen other
mtDNA SNPs (m.1811G, m.3010A, m.4336C, m.4580A, m.
4769A, m.9477A, m.10873C, m.13708A, m.14766C, m.
14793G, m.14798C, m.15218G, m.15257A, m.15693C) were
analyzed using a hierarchic approach, taking into account
haplogroup frequencies in the general Spanish population, to
confirm particular haplogroups (Figure 1) [9]. The revised
Cambridge Reference Sequence was used to define mtDNA
position and nucleotide [13]. The RT-PCR was performed with
TaqMan reagents (Applied Biosystems, Austin, TX). For each
SNP, reagents included two primers around the SNP and two
probes: a fluorophore vic-labelled probe specific for one allele
and another fluorophore FAM-labelled probe specific for the
other allele. DNA was amplified in a final volume of 25 µl, using
12.5 µl of TaqMan Gene Expression Master Mix, 0.9 µM of
each primer, 0.2 µM of each probe and 10 ng of total DNA. The
amplification was performed using universal conditions.
Statistical analysis
We determined 30-days and 6-month survival and mtDNA
haplogroup in the first cohort of 96 patients, second cohort of
196 patients and in the global cohort (first and second cohorts
combined) with 292 severe septic patients.
Continuous variables are reported as medians and
interquartile ranges, and were compared using Wilcoxon-
Mann-Whitney test. Categorical variables are reported as
frequencies and percentages, and were compared by chi-
square test.
Multiple logistic regression and Cox regression analyses
were used to test the association of mtDNA haplogroup JT with
survival at 30 days and 6 months, controlling for age, sex,
serum interleukin-6 levels and SOFA score. We used a step-
by-step approach to select the variables included in the
multivariable analysis; that is, we included in the final model
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those independent variables that allowed us to predict
mortality. Odds Ratios and their 95% confidence intervals were
calculated as measures of the association.
Survival analysis with Kaplan-Meier curve method and log-
rank test comparisons were carried out using mtDNA
haplogroup JT versus non-JT as the independent variable and
survival at 30 days and 6 months as the dependent variable.
Differences with a P value of less than 0.05 were considered
statistically significant. Statistical analyses were performed
using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Med Calc
(Maria Kerke, Belgium).
Results
In the global cohort (first and second cohort combined),
patients with mtDNA haplogroup JT (n=46) showed significantly
higher survival than patients with other haplogroups (n=246) at
30 days (82.6% vs 63.4%; p=0.007) and 6 months (76.1% vs
52.4%; p=0.002) (Table 1). Multiple logistic regression and Cox
regression analyses showed that mtDNA haplogroup JT was
associated with higher survival at 30-days or 6 months after
controlling for age, sex, serum interleukin-6 levels and SOFA
score (Table 2).
In the first cohort (n=96) we found no significant differences
between patients with the mtDNA haplogroup JT (n=15) and
other haplogroups (n=81) in survival at 30 days (86.7% vs
61.7%; p=0.17) and 6 months (73.3% vs 53.1%; p=0.08) (Table
Figure 1.  Mitochondrial DNA haplogroups.  Haplogroup
nomenclature is denoted in bold. N* defines those N non HV,
JT or U individuals. HV* defines HV non H individuals. H*
defines H non H1, H2 or H5 individuals. U5a* defines U5a non
U5a1 individuals. U1811* defines U1811 non U4 or UK
individuals. U* defines U non U4, UK, U1811* or U5
individuals. J1* defines J1 non J1c individuals. A)
Haplogrouping strategy. The three numbers in brackets
indicate the number of patients from each haplogroup and the
number of one- and six-months survivors. B) Phylogeny
summarizing the relationship between different mtDNA
haplogroups.
doi: 10.1371/journal.pone.0073320.g001
S1). Multiple logistic regression and Cox regression analyses
did not show that mtDNA haplogroup JT was associated with
higher survival at 30-days or 6 months, after controlling for age,
sex, serum interleukin-6 levels and SOFA score (Table S3).
In the second cohort (n=196), patients with mtDNA
haplogroup JT (n=31) showed a trend to higher survival at 30
days (80.6% vs 64.2%; p=0.054) and significantly higher
survival at 6 months (77.4% vs 52.1%; p=0.007) than patients
with other haplogroups (n=165) (Table S2). Multiple logistic
regression and Cox regression analyses showed a non-
significant association between mtDNA haplogroup JT and
higher survival at 30 days or 6 months after controlling for age,
sex, serum interleukin-6 levels and SOFA score (Table S3).
Kaplan-Meier analysis confirmed a higher survival rate of
patients with mtDNA haplogroup JT at 30 days (log-rank
test=5.84; p=0.016) and 6 months (log-rank test=7.90;
p=0.005) in the global cohort (Figure 2).
To check whether the association of haplogroup JT with a
higher survival rate was due to SNPs defining this cluster or
because of over-representation of one of the two sub-
haplogroups that integrate the cluster, we separated our JT
samples into sub-haplogroups J (n=11) and T (n=35). There
were no significant differences between J and T sub-
haplogroups in survival at 30 days [8/11 (72.7%) vs 30/35
(85.7%); p=0.37] and 6 months [8/11 (72.7%) vs 27/35
(77.1%); p=0.99]. Therefore, haplogroup JT-defining single
nucleotide polymorphisms are probably responsible for the
decreased risk of death from severe sepsis.
Since previously published work has shown that haplogroup
H septic patients were more likely to survive to six months, we
also studied survival of haplogroup H patients in our sample.
There were no significant differences between haplogroup H
and non-H patients in survival at 30 days [66/106 (62.3%) vs
128/186 (68.8%); p=0.30] and 6 months [55/106 (51.9%) vs
109/186 (58.6%); p=0.27]. In our sample these patients did not
present a lower risk of early mortality.
Similarly, because previous publications have shown
improved 6-month survival in haplogroup R septic patients, we
also analyzed haplogroup R patient survival in our sample.
Although 24 patients from N* lineages were not separated into
R and non-R lineages, we found no significant differences
between haplogroup R and non-R individuals in 30-day survival
[166/246 (67.5%) vs 15/22 (68.2%); p=0.99] or 6-month
survival [136/246 (55.3%) vs 15/22 (68.2%); p=0.27]. Thus in
our sample, these patients did not present a lower risk of early
mortality.
Discussion
The global cohort study (first and second cohorts combined)
is the largest to date reporting on mtDNA haplogroups in septic
patients. The study confirmed that haplogroup JT septic
patients showed increased 30-day and 6-month survival than
non-JT haplogroup patients.
In addition, we previously found that sepsis patients surviving
at least six-months had greater amounts of platelet cytochrome
oxidase than those who died in this period [14,15] and that
haplogroup JT patients had greater amounts of platelet
Mitochondrial DNA Haplogroup and Sepsis Survival
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cytochrome oxidase than patients with other mtDNA clusters
[9]. As biologic plausibility is enhanced when a given
polymorphism (haplogroup JT) is associated with a clinical
phenotype (lower mortality due to severe sepsis) and an
intermediate phenotype (higher cytochrome oxidase quantity)
[4], all these results suggest that haplogroup JT modifies the
risk of early death in septic patients. Because the survival rates
were very similar between haplogroup JT sub-groups (sub-
Table 1. Patients’ demographic and clinical characteristics according to mtDNA haplogroups of the 292 patients of global
cohort (first and second cohort combined).
 
HV
(n=129)
U
(n=71)
No R
(n=46)
Total
Non JT
(n=246)
JT
(n=46)
p
JT vs Non JT
Gender male -n (%) 90 (69.8) 49 (69.0) 28 (60.9) 167 (67.9) 27 (58.7) 0.24
Age - median years (p 25-75) 61 (50-71) 61 (51-73) 61 (45-71) 61 (49-71) 57 (49-70) 0.42
Diabetes Mellitus -n (%) 42 (32.6) 22 (31.0) 10 (21.7) 74 (30.1) 10 (21.7) 0.29
COPD -n (%) 18 (14.0) 9 (12.7) 4 (8.7) 31 (12.6) 8 (17.4) 0.35
Ischemic heart disease -n (%) 15 (11.6) 7 (9.9) 5 (10.9) 27 (11.0) 3 (6.5) 0.44
Site of infection      0.51
- Respiratory -n (%) 78 (60.5) 43 (60.6) 23 (50.0) 144 (58.5) 23 (50.0)  
- Abdominal -n (%) 30 (23.3) 18 (25.3) 16 (34.8) 65 (26.4) 15 (32.6)  
- Neurological -n (%) 3 (2.3) 1 (1.4) 1 (2.2) 5 (2.0) 1 (2.2)  
- Urinary -n (%) 6 (4.6) 3 (4.2) 2 (4.3) 11 (4.5) 4 (8.7)  
- Skin -n (%) 4 (3.1) 2 (2.8) 4 (8.7))
9 (3.7)
) 3 (6.5)  
- Endocarditis -n (%) 7 (5.4) 4 (5.6) 0 (0) 11 (4.5) 0 (0)  
- Osteomyelitis -n (%) 1 (0.8) 0 (0) 0 (0) 1 (0.4) 0 (0)  
Microorganism responsibles       
- Unkwon -n (%) 66 (51.2) 37 (52.1) 23 (50.0) 126 (51.2) 20 (43.5) 0.42
- Gram-positive- n (%) 30 (23.3) 19 (26.8) 11 (23.9) 60 (24.4) 14 (30.4) 0.46
- Gram-negative- n (%) 31 (24.0) 16 (22.5) 12 (26.1) 59 (24.1) 12 (26.1) 0.85
- Fungii- n (%) 5 (3.9) 2 (2.8) 1 (2.2) 8 (3.3) 0 (0) 0.36
- Anaerobe- n (%) 1 (0.8) 0 (0) 1 (2.2) 2 (0.8) 1 (2.2) 0.40
Bloodstream infection 21 (16.3) 7 (9.9) 10 (21.7) 38 (15.4) 9 (19.6) 0.51
Empiric antimicrobial treatment adequate      0.58
- Unkown due to negative cultures- n (%) 66 (51.2) 36 (50.7) 23 (50.0) 125 (50.8) 20 (43.5)  
- Adequate -n (%) 49 (38.0) 30 (42.3) 22 (47.8) 101 (41.1) 20 (43.5)  
- Unkown due to antigenuria diagnosis- n (%) 3 (2.3) 2 (2.8) 1 (2.2) 6 (2.4) 2 (4.3)  
- Inadequate- n (%) 11 (8.5) 3 (4.2) 0 (0) 14 (5.7) 4 (8.7)  
Betalactamic more aminoglycoside- n (%) 28 (21.7) 15 (21.1) 10 (21.7) 53 (21.5) 11 (23.9) 0.70
Betalactamic more quinolone- n (%) 61 (47.3) 40 (56.3) 27 (58.7) 128 (52.0) 22 (47.8) 0.63
Septic shock- n (%) 110 (85.3) 60 (84.5) 40 (87.0) 210 (85.4) 41 (89.1) 0.65
PaO2/FIO2 ratio - median (p 25-75) 180 (121-257) 150 (86-250) 168 (93-328) 175 (106-260) 161 (104-252) 0.51
Creatinine (mg/dl) - median (p 25-75) 1.40 (0.85-2.50) 1.40 (0.90-2.00) 1.40 (0.70-2.60) 1.40 (0.90-2.35) 1.55 (0.97-2.85) 0.47
Bilirubin (mg/dl) - median (p 25-75) 1.00 (0.57-2.10) 0.90 (0.60-1.57) 0.85 (0.40-1.97) 0.94 (0.56-1.90) 1.30 (0.47-1.50) 0.56
Leukocytes -median*103/mm3 (p 25-75) 15.2 (9.3-20.3) 11.9 (6.1-22.0) 12.8 (8.6-15.7) 14.0 (8.7-20.0) 15.9 (11.5-25.7) 0.89
Lactic acid - median mmol/L (p 25-75) 2.30 (1.20-4.55) 2.60 (1.40-4.20) 2.10 (0.90-4.70) 2.26 (1.20-4.40) 2.60 (1.25-4.05) 0.77
Platelets - median*103/mm3 (p 25-75) 176 (99-238) 192 (83-317) 196 (87-245) 179 (97-255) 145 (96-221) 0.17
INR - median (p 25-75) 1.40 (1.10-1.69) 1.29 (1.11-1.56) 1.33 (1.12-1.52) 1.33 (1.11-1.59) 1.24 (1.14-1.51) 0.56
aPTT - median seconds (p 25-75) 33 (28-43) 35 (29-41) 34 (28-50) 33 (28-43) 31 (27-42) 0.86
Interleukin-6 (pg/ml) - median (p 25-75) 110 (37-984) 171 (42-1070) 301 (45-1075) 161 (42-1012) 314 (32-1010) 0.59
SOFA score - median (p 25-75) 9 (7-12) 10 (8-12) 9 (7-12) 9 (7-12) 9 (7-12) 0.84
APACHE-II score - median (p 25-75) 20 (16-26) 20 (15-24) 21 (16-23) 20 (16-25) 20 (15-23) 0.52
Survivors at 30 days- n (%) 83 (64.3) 45 (63.4) 28 (60.9) 156 (63.4) 38 (82.6) 0.007
Survivors at 6 months- n (%) 69 (53.5) 36 (50.7) 24 (52.2) 129 (52.4) 35 (76.1) 0.002
COPD = chronic obstructive pulmonary disease; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; INR = International normalized ratio; aPTT = Activated
partial thromboplastin time; SOFA = Sepsis-related Organ Failure Assessment; APACHE-II = Acute Physiology and Chronic Health Evaluation-II score. Data are presented
as number (percentage) or median (interquartile range)
doi: 10.1371/journal.pone.0073320.t001
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Table 2. Multiple logistic regression (MLR) and Cox
regression analyses to predict mortality in the 292 patients
of global cohort (first and second cohort combined).
 MLR OR (95% CI); p-value
Cox regression OR (95%
CI); p-value
Model: Mortality at 30
days in global cohort
of 292 patients
  
mtDNA haplogroup JT 0.38 (0.15–0.95); 0.04 0.48 (0.22–0.97); 0.04
Serum Interleukin-6
levels
1.001 (1.0001-1.0015);
0.01
1.001 (1.0001-1.0015);
<0.001
Age 1.16 (0.99–1.03); 0.16 1.16 (0.999–1.03); 0.05
Sex female 1.20 (0.66-2.19); 0.55 1.15 (0.73-1.79); 0.55
SOFA 1.15 (1.06–1.24); 0.001 1.15 (1.08–1.21); <0.001
Model: Mortality at 6
months in global
cohort of 292
patients
  
mtDNA haplogroup JT 0.40 (0.17–0.90); 0.03 0.51 (0.26–0.97); 0.04
Serum Interleukin-6
levels
1.0005 (0.999-1.001);
0.052
1.0005 (1.0001-1.001);
0.001
Age 1.02 (1.004–1.042); 0.02 1.02 (1.006–1.034); 0.005
Sex female 1.18 (0.67-2.09); 0.56 1.14 (0.77-1.70); 0.52
SOFA 1.15 (1.06–1.24); <0.001 1.12 (1.07–1.18); <0.001
OR = Odds Ratio; CI = Confidence Interval; SOFA = Sepsis-related Organ Failure
Assessment
doi: 10.1371/journal.pone.0073320.t002
Figure 2.  Cumulative proportion of patients' survival at
30 days and 6 months according to mtDNA haplogroup JT
versus no JT.  
doi: 10.1371/journal.pone.0073320.g002
haplogroup J and sub-haplogroup T), then single nucleotide
polymorphisms defining the whole haplogroup JT appear to be
responsible for this association.
Four polymorphisms define haplogroup JT: m.4216C, m.
11251G, m.15452A and m.16126C. The second is a
synonymous polymorphism and does not change the amino
acid in the polypeptide sequence and the last is located in the
control region but it does not affect important regions involved
in the regulation of replication or transcription. Therefore, m.
4216TC, which provokes a p.MT-ND1:Y304H substitution, or
m.15452CA, which produces a p.MT-CYB:L236I replacement,
are the best candidates to explain these results. In m.15452CA
there is a C to A transversion at mtDNA nucleotide position
15452 (m codes for mtDNA). In p.MT-CYB:L236I there is a
replacement of leucine at cytochrome b amino acid position
236 by an isoleucine (p codes for protein). Interestingly, the m.
4216T polymorphism, as in non-JT lineages, has been found to
increase the risk of in-hospital mortality after severe injury in
525 white patients [16]. However, m.4216C, as in haplogroup
JT, has also been shown to increase the risk of death in 136
patients after severe trauma [17]. In any case, and due to the
complete linkage disequilibrium in the mtDNA, other SNPs
linked to m.4216C could be responsible for the effect. In this
scenario, the genotyping of only m.4216 position could produce
opposing results. In fact, in addition to the European
haplogroup JT, m.4216C has been also found defining Asian
(D5c, M2a1b, M2c, M14), Australian (P4a), African (L4b1) and
European (H10a) haplogroups [18]. Thus, the analysis of more
than one haplogroup-defining SNP is necessary to target the
causal polymorphism o combination of polymorphisms.
MtDNA genetic variation can alter the expression of nuclear
genes [19]. Cybrids are cell lines that share the nuclear genetic
background and culture conditions and only differ in the mtDNA
genotype. Therefore, phenotypic differences between them
must be due to the mtDNA genotype they harbour [20]. Very
interestingly, it has been shown that, under stress conditions,
IL-6 mRNA is more expressed in H than J cybrids [21]. Thus,
these results suggest that, as haplogroup J expresses less IL-6
mRNA and IL-6 levels are positively associated with ICU
mortality [22,23], the protective effect of mtDNA haplogroup JT
against mortality by severe sepsis could be also through a
lower production of this cytokine. In our study we found that
serum IL-6 levels were associated with mortality. as previously
described [22,23]. However, we found no differences in serum
IL-6 levels between different mtDNA haplogroups.
The fact that we did not find any survival differences between
R and non-R lineages of European septic patients is not
surprising. MtDNA haplogroup R is defined by m.12705CT and
m.16223CT polymorphisms. The first is a synonymous
polymorphism and the second is located in the control region
but it does not affect important regions involved in regulation or
transcription. Therefore, the association between R lineages
and sepsis survival in Chinese patients [7,8] must be due to an
over-representation of R sub-haplogroups, such as B or F, that
are not present in the European population.
A similar explanation cannot apparently be advanced for our
different results in relation to haplogroup H. This association
between haplogroup H and sepsis survival in English patients
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was for the whole haplogroup and not for particular sub-
haplogroups [6]. It is unclear in this study how statistically
significant confounders such as age, SOFA score and
APACHE were controlled. However, in our study, patients with
different haplogroups did not show differences in these
possible confounders. In addition, we did not find significant
differences in several parameters such as the causal
microorganism of sepsis, the presence of bloodstream infection
and the antimicrobials used, but these variables were not
reported for the English patients [6].
Some limitations of this analysis should be recognized. For
example, we only determined cytochrome oxidase quantity in
96 [9] out of the 292 patients examined in this work, although
this is the only study on sepsis survival and mtDNA
haplogroups that has included the measurement of an
intermediate phenotype besides the association between
genetic data and clinical phenotype. Sepsis survival probably
depends on many different factors and, although our study
represents the largest series reporting severe sepsis mortality
according to mtDNA haplogroup, if we take into account these
other factors then greater sample sizes should be considered
for future studies.
Conclusion
This global cohort study (first and second cohort combined)
is the largest to date reporting on mtDNA haplogroups in septic
patients. The study confirmed that haplogroup JT septic
patients show increased 30-day and 6-month survival. This
finding may be due to single nucleotide polymorphism defining
the whole haplogroup JT and not separately for J or T sub-
haplogroups.
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